1. Dosage
1.1. Adults
Direct oral anticoagulants (DOACs) are FDA-approved to treat and prevent deep venous thrombosis (DVT) and pulmonary embolism (PE), reduce the risk of stroke and systemic embolism from non-valvular atrial fibrillation, and to be used as prophylaxis against DVT and PE after knee and hip surgery. DOACs work by interfering with pathways in the coagulation cascade: directly inhibiting thrombin (e.g., dabigatran); or selectively, reversibly inhibiting factor Xa (e.g., apixaban, edoxaban, rivaroxaban)1-7. In April 2020, Portola Pharmaceuticals removed Bevyxxa® (betrixaban) from the market for independent business reasons8 .
Maximum recommended adult dosages for DOACs are summarized in Tables 1 and 2. Medication profiles identifying patients prescribed dosages exceeding these recommendations will be reviewed.
Drug Name | Dosage Form/Strength | Treatment Indication | Maximum Recommended Dosage |
---|---|---|---|
dabigatran (Pradaxa®) | 75 mg, 110 mg, 150 mg capsules | Reduction in risk of stroke and systemic embolism in non-valvular AF |
|
dabigatran | Treatment of DVT and PE/reduction in the risk of recurrence of DVT and PE |
|
|
dabigatran | Prophylaxis of DVT and PE following hip replacement surgery |
|
|
Legend:
- AF = atrial fibrillation
- DVT = deep venous thrombosis
- PE = pulmonary embolism
- *Requires 5 to 10 days parenteral therapy before initiation of therapy
Drug Name | Dosage Form/Strength | Treatment Indication | Maximum Recommended Dosage |
---|---|---|---|
apixaban (Eliquis®) | 2.5 mg, 5 mg tablets | Reduction of risk of stroke and systemic embolism in patients with non-valvular AF | 5 mg twice daily# |
apixaban | Prophylaxis of DVT following hip or knee replacement surgery | 2.5 mg twice daily | |
apixaban | Treatment of DVT and PE | 10 mg twice daily for 7 days, then 5 mg twice daily | |
apixaban | Reduction in risk of recurrence of DVT and PE | 2.5 mg twice daily^ | |
edoxaban (Savaysa®) | 15 mg, 30 mg, 60 mg tablets |
Non-valvular AF: CrCl greater than 50 mL/min and less than or equal to 95 mL/min |
60 mg once daily+ |
edoxaban |
Non-valvular AF: CrCl 15-50 mL/min |
30 mg once daily | |
edoxaban |
Treatment of DVT and PE: greater than or equal to 60 kg |
60 mg once daily* | |
edoxaban |
Treatment of DVT and PE: less than 60 kg, CrCl 15-50 mL/min, adjunctive therapy with certain P-gp inhibitors |
30 mg once daily* | |
rivaroxaban (Xarelto®) | 2.5 mg, 10 mg, 15 mg, 20 mg tablets, 1 mg/ 1 mL granules for suspension | Reduction in the risk of stroke in non-valvular AF, CrCl greater than 50 mL/min | 20 mg once daily with evening meal |
rivaroxaban | Reduction in the risk of stroke in non-valvular AF, CrCl less than or equal to 50 mL/min | 15 mg once daily with evening meal | |
rivaroxaban | Treatment of DVT and PE, CrCl greater than or equal to 15 mL/min | 15 mg twice daily for 21 days, then 20 mg once daily | |
rivaroxaban | Reduction in risk of recurrence of DVT and PE (following initial treatment), CrCl greater than or equal to 15 mL/min | 10 mg once daily^ | |
rivaroxaban | Prophylaxis of DVT following hip or knee replacement surgery, CrCl greater than or equal to 15 mL/min | 10 mg once daily | |
rivaroxaban | VTE prophylaxis in hospitalized adults with acute illness and limited mobility and other risk factors for VTE, CrCl greater than or equal to 15 mL/min | 10 mg once daily | |
rivaroxaban | Reduction of major cardiovascular event risk in patients with chronic coronary heart disease, peripheral artery disease | 2.5 mg twice daily, plus aspirin 75-100 mg once daily |
Legend
- AF = atrial fibrillation
- DVT = deep venous thrombosis
- PE = pulmonary embolism
- P-gp = P-glycoprotein
- VTE = venous thromboembolism
- + Avoid in patients with CrCl greater than 95 ml/min due to increased risk of ischemic stroke compared to warfarin
- * Requires 5 to 10 days parenteral therapy before initiation of therapy
- # Dose should be decreased to 2.5 mg twice daily in patients receiving strong inhibitors of both CYP3A4 and P-glycoprotein concurrently, or those with at least two of the following: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL
- ^ Following at least 6 months of DVT or PE treatment
1.2. Pediatrics
Apixaban and edoxaban are not recommended for use in pediatric patients, as the safety and efficacy have not been established for these agents in this patient population .1,2,5,6 .
In June 2021, the FDA approved Pradaxa® (dabigatran) oral pellets to treat venous thromboembolism after receiving at least five days of injectable or intravenous treatment for blood clots and to reduce the risk of recurrent thromboembolism in patients 3 months to less than twelve years of age who have completed treatment for a previous venous thromboembolism9.
Dabigatran oral capsules were approved to treat venous thromboembolism after receiving at least five days of injectable or intravenous treatment for blood clots and to reduce the risk of recurrent thromboembolism in patients 8 years of age and older who have completed treatment for a previous venous thromboembolism9.
In December 2021, the FDA approved Xarelto® (rivaroxaban) tablets and oral suspension to treat venous thromboembolism and to reduce the risk of recurrent venous thromboembolism in patients less than 18 years of age who received at least five days of injectable or intravenous treatment for blood clots. Rivaroxaban was also approved to reduce the risk of blood clots in patients two years of age and older with congenital heart disease after the Fontan procedure10 .
Maximum recommended pediatric dosages for DOACs are summarized in Table 3 through Table 6. Medication profiles identifying patients prescribed dosages exceeding these recommendations will be reviewed.
Drug Name | Dosage Form/Strength | Treatment Indication | Maximum Recommended Dosage |
---|---|---|---|
dabigatran (Pradaxa®) oral pellets! | 20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg oral pellets | Treatment of VTE and to reduce the risk of VTE recurrence: 3 months to less than or equal to 2 years of age |
|
Legend
- VTE = venous thromboembolism
- ! Avoid dabigatran in patients with a CrCl less than 50 mL/min
- * Requires at least 5 days of parenteral therapy before initiation of therapy for the treatment of VTE
- ^ Following appropriate treatment duration of DVT or PE treatment if used to reduce the risk of VTE recurrence
Drug Name | Dosage Form/Strength | Treatment Indication | Maximum Recommended Dosage |
---|---|---|---|
dabigatran (Pradaxa®) oral pellets! | 20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg oral pellets | Treatment of VTE and to reduce the risk of VTE recurrence: 2 to less than 12 years of age |
|
Legend
- VTE = venous thromboembolism
- ! Avoid dabigatran in patients with a CrCl less than 50 mL/min
- * Requires at least 5 days of parenteral therapy before initiation of therapy for the treatment of VTE
- ^ Following appropriate treatment duration of DVT or PE treatment if used to reduce the risk of VTE recurrence
Drug Name |
Dosage Form/Strength |
Treatment Indication | Maximum Recommended Dosage |
---|---|---|---|
dabigatran (Pradaxa®) capsules! | 75 mg, 110 mg, 150 mg oral capsules | Treatment of VTE and to reduce the risk of VTE recurrence: 8 to less than 18 years of age | 11 kg to less than 16 kg*^ 75 mg twice daily 16 kg to less than 26 kg*^ 110 mg twice daily 26 kg to less than 41 kg*^ 150 mg twice daily 41 kg to less than 61 kg*^ 185 mg twice daily 61 kg to less than 81 kg*^ 220 mg twice daily 81 kg or greater*^ 260 mg twice daily |
Legend
- VTE = venous thromboembolism
- ! Avoid dabigatran in patients with a CrCl less than 50 mL/min
- * Requires at least 5 days of parenteral therapy before initiation of therapy for the treatment of VTE
- ^ Following appropriate treatment duration of DVT or PE treatment if used to reduce the risk of VTE recurrence
Drug Name | Dosage Form/Strength | Treatment Indication | Maximum Recommended Dosage± |
---|---|---|---|
rivaroxaban (Xarelto®) | 10 mg, 15 mg, 20 mg tablets, 1 mg/ 1 mL granules for suspension | Treatment of VTE and to reduce the risk of VTE recurrence: less than 18 years of age |
|
Thromboprophylaxis in patients 2 years of age and older with congenital heart disease who have undergone Fontan procedure |
|
Legend
- VTE = venous thromboembolism
- ± Patients less than 6 months of age should meet the following criteria: at birth at least 37 weeks gestation, have at least 10 days of oral feeding, and weigh greater than or equal to2.6 kg at the time of dosing
- * Requires at least 5 days parenteral therapy before initiation of therapy for treatment of VTE
- ^ Following appropriate treatment duration of DVT or PE treatment if used to reduce the risk of VTE recurrence
- # May only use granules for suspension
- ! May use granules for suspension or oral tablets